LH Blood Test Explained: What Luteinising Hormone Measures and How Results Are Reported

Luteinising hormone (LH) is a glycoprotein hormone released by the anterior pituitary gland. An LH blood test quantifies how much of that hormone is circulating in serum or plasma at the moment the sample was drawn. Because LH acts on the gonads — the ovaries in females and the Leydig cells of the testes in males — clinicians and researchers use the measurement as a window onto the hypothalamic–pituitary–gonadal (HPG) axis rather than as a stand-alone number.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any test, result or symptom. Nothing here interprets an individual result or suggests any course of action.

What LH Is and What the Blood Test Measures

LH is secreted in pulses under the control of gonadotropin-releasing hormone (GnRH) from the hypothalamus. It shares a common alpha subunit with FSH, TSH and hCG, and carries a distinct beta subunit that gives it specificity at the LH receptor. Research characterising gonadotropin receptors across species has confirmed that LH and FSH receptors respond to their respective ligands with distinct activation profiles, as researchers reported when functionally characterising follicle-stimulating hormone and luteinizing hormone receptors in the cloudy catshark (PMID 38685391).

In practical laboratory terms, "LH in bloodwork" is an immunoassay result: antibodies bind the intact LH heterodimer, and the signal generated is converted to a concentration, almost always expressed in international units per litre (IU/L), sometimes written as mIU/mL (numerically the same value). The assay does not measure LH activity at the receptor; it measures immunoreactive hormone present in the tube.

What an LH Blood Test Shows

• Pituitary output. Whether the gland is releasing gonadotropin at all, and roughly how much.
• Axis direction. Interpreted alongside FSH and the sex steroids (oestradiol or testosterone), LH helps distinguish a gonadal problem (low sex steroid with high LH) from a pituitary or hypothalamic one (low sex steroid with low or inappropriately normal LH).
• Cycle position, in females. A mid-cycle surge precedes ovulation, so a single value is only meaningful when the day of the cycle is known.
• Pubertal activation, in children. Rising basal and stimulated LH is a central feature of the diagnostic literature on precocious puberty.

LH Blood Test in Females: How Results Are Reported

In menstruating women, LH is not a flat number. Laboratories therefore report several reference intervals on the same sheet — typically follicular phase, mid-cycle (ovulatory) peak, luteal phase and postmenopausal — and the result must be read against the interval matching the day the blood was drawn. Because of this variability, a methodological framework for menstrual cycle research in sports and exercise set out recommendations for verifying cycle phase rather than assuming it, and researchers described serum hormone measurement and urinary LH surge detection among the verification approaches available to investigators (PMID 31246715).

The ovulatory surge is the single most-discussed LH feature in female testing. It is brief, which is exactly why a study designed around it has to sample frequently or use a home urinary method; a one-off venous draw can easily fall before or after the peak. Reviews of personal fertility monitoring compared quantitative and qualitative approaches to oestrogen and LH testing and discussed how threshold-based qualitative devices differ from quantitative readouts when tracking the surge (PMID 34714210).

Gonadotropin measurement is also used at the other end of the age range. A prospective cohort study of minipuberty in girls with Turner syndrome examined early-infancy gonadotropin and hormone profiles and reported that this window offered insight into later reproductive potential (PMID 40651522).

LH Blood Test in Men: What the Literature Describes

In males, LH stimulates testicular Leydig cells to produce testosterone, and testosterone in turn feeds back on the hypothalamus and pituitary. Unlike the female cycle, male LH does not follow a monthly pattern, but it is still pulsatile across the day, so consecutive samples from the same person can differ.

The interpretive logic reported in clinical literature pairs LH with testosterone:

Low gonadotropins alongside other deficient pituitary axes point toward broader pituitary pathology. A case report of atypical panhypopituitarism described a presentation in which multiple anterior pituitary hormone deficiencies were identified together, illustrating why gonadotropins are rarely measured in isolation (PMID 32789047).

What Is a "Normal Range" for LH?

There is no single universal LH number. Reference intervals are assay-specific and population-specific, which means the range printed by one laboratory may not transfer to another that uses a different antibody pair, calibrator or platform. Three factors drive this:

1. Sex and age. Prepubertal, reproductive-age, and postmenopausal intervals differ substantially; postmenopausal values are typically the highest reported in adult women because ovarian feedback has fallen away.
2. Cycle phase. In females, the mid-cycle interval sits well above the follicular interval on the same report.
3. Assay sensitivity at the low end. Distinguishing "low" from "undetectable" matters most in children and in suspected central deficiency, and depends on the functional sensitivity of the platform. Work developing a modified ultra-sensitive ELISA for measurement of LH in mice was undertaken specifically because conventional assays struggled at very low concentrations, and researchers reported an approach designed to improve low-end detection (PMID 35869782).

Species-specific assay development shows the same principle. Researchers established a specific ELISA for measuring FSH and LH in medaka using recombinant gonadotropins, because no cross-reactive human assay could be assumed to be valid in that species (PMID 31293904). The general lesson carried by that literature is that an LH value only means something against the reference material and method that produced it.

Basal Versus Stimulated LH

Some questions cannot be answered by a resting sample. In paediatric endocrinology, a GnRH (or GnRH-agonist) stimulation test is used: a stimulus is given and LH is measured at set intervals afterwards, with the peak value compared against a diagnostic cutoff. A mini review of the GnRH stimulation test and diagnostic cutoffs in precocious puberty discussed how cutoff values depend on the assay generation used, and researchers noted that cutoffs derived from older radioimmunoassays do not transfer directly to modern immunochemiluminometric platforms (PMID 32871650).

Clinical overviews echo this. A review on the diagnosis of central precocious puberty described the role of basal and stimulated LH measurement within the overall diagnostic workup (PMID 38677865), and an "Approach to the Patient" article on central precocious puberty set out how gonadotropin testing is combined with clinical and imaging findings (PMID 36916130).

Timing: When LH Blood Tests Are Typically Drawn

Timing is a measurement-quality issue rather than a matter of personal preference, and the literature frames it in three ways.

Cycle Timing in Females

Because reference intervals are phase-specific, the cycle day of the draw is part of the result. Methodological recommendations for menstrual cycle research emphasised documenting and verifying cycle phase so that hormone data could be interpreted consistently across participants, and researchers described serum sampling and urinary LH surge detection as verification tools (PMID 31246715).

Time of Day and Pulsatility

LH is released in pulses, so a single sample captures one point on a fluctuating curve. This is why protocols investigating low-level secretion often use repeated sampling or higher-sensitivity assays; the ultra-sensitive ELISA work in mice was motivated by the need to resolve pulsatile, low-concentration LH that routine assays could miss (PMID 35869782).

Stimulation-Test Timing

In stimulation protocols, sampling times are fixed by the protocol itself, with the peak value — not a random value — compared to the published cutoff, as discussed in the GnRH stimulation test mini review (PMID 32871650).

Fasting, Handling and Turnaround

LH is a peptide hormone measured by immunoassay, and the published methodological literature on gonadotropin assays focuses on antibody specificity, calibration and sensitivity rather than on food intake before the draw (PMID 31293904). Whether fasting is requested is set by the ordering laboratory's own protocol, frequently because other analytes on the same requisition (such as glucose or lipids) require it. Anyone with a specific preparation question is directed to the laboratory or clinician who ordered the test.

Sample handling, as a measurement concept. Immunoassay results depend on the integrity of the analyte between collection and analysis. Assay-development papers describe validating a method against defined sample matrices and handling conditions before results are considered reliable; the medaka ELISA work built its method around recombinant gonadotropin standards for exactly this reason (PMID 31293904). This is measurement education, not handling instruction.

How Long the Test Takes

The blood draw itself is a routine venepuncture lasting a few minutes. Analytical time and reporting time are separate matters determined by the laboratory's platform, batching schedule and workflow — a dedicated stimulation test, by contrast, takes as long as the protocol's sampling schedule dictates, since multiple timed samples are required (PMID 32871650). Turnaround expectations come from the testing laboratory, and published assay literature does not define them.

Blood Test Versus Urine Test for LH

Both matrices are used, and they answer different questions. Serum LH gives a quantitative concentration comparable to a laboratory reference interval. Urinary LH testing, including home ovulation predictor kits, generally detects whether LH has crossed a threshold. A review comparing quantitative and qualitative oestrogen and LH testing for personal fertility monitoring examined this distinction and discussed how the two formats differ in the information they return (PMID 34714210).

Device development continues in both directions. Researchers described a point-of-care impedimetric aptasensor built to detect luteinizing hormone, reporting an electrochemical approach intended for rapid near-patient measurement rather than central-laboratory immunoassay (PMID 38286844).

Measurement Limitations: What Studies Report

The recurring caution across this literature concerns comparability. Researchers reported that diagnostic cutoffs for stimulated LH in precocious puberty vary with the assay generation used, so a numerical threshold cannot be lifted from one method and applied to another (PMID 32871650). Sensitivity at the low end is a second limitation, which is why a modified ultra-sensitive ELISA was developed for LH measurement in mice (PMID 35869782). A third is context: clinical reviews of central precocious puberty described gonadotropin values being interpreted alongside clinical staging and imaging rather than alone (PMID 36916130), and a panhypopituitarism case report illustrated how an isolated hormone value can under-represent a multi-axis picture (PMID 32789047).

No adverse-event data specific to the act of LH measurement are described in the verified literature summarised here; the papers cited address assay methodology and diagnostic interpretation.

Key Points

• LH is a pituitary gonadotropin; the blood test reports its concentration, usually in IU/L.
• Female reference intervals are split by cycle phase and menopausal status; male values are non-cyclical but pulsatile.
• Reference ranges and diagnostic cutoffs are assay-specific, a point researchers emphasised in the GnRH stimulation test literature (PMID 32871650).
• Urinary LH testing answers a threshold question; serum testing answers a quantitative one (PMID 34714210).
• Interpretation is done by a clinician with the full clinical picture.

References

• Atypical Presentation of Panhypopituitarism (Cureus, 2020)
• Methodological Recommendations for Menstrual Cycle Research in Sports and Exercise (Medicine and Science in Sports and Exercise, 2019)
• Diagnosis of Central Precocious Puberty (Endocrinology and Metabolism Clinics of North America, 2024)
• Approach to the Patient: Central Precocious Puberty (The Journal of Clinical Endocrinology and Metabolism, 2023)
• Minipuberty in girls with Turner syndrome provides insight into reproductive potential-a prospective cohort study (Fertility and Sterility, 2025)
• A Modified Ultra-Sensitive ELISA for Measurement of LH in Mice (Endocrinology, 2022)
• Case of Anorchia in a Mixed-Breed Dog (Topics in Companion Animal Medicine, 2021)
• Quantitative versus qualitative estrogen and luteinizing hormone testing for personal fertility monitoring (Expert Review of Molecular Diagnostics, 2021)
• Gonadotropin-releasing hormone stimulation test and diagnostic cutoff in precocious puberty: a mini review (Annals of Pediatric Endocrinology & Metabolism, 2020)
• Functional characterization of follicle-stimulating hormone and luteinizing hormone receptors in cloudy catshark, Scyliorhinus torazame (General and Comparative Endocrinology, 2024)
• Point-of-care impedimetric aptasensor to detect the luteinizing hormone (Mikrochimica Acta, 2024)
• Establishment of specific enzyme-linked immunosorbent assay (ELISA) for measuring Fsh and Lh levels in medaka (Oryzias latipes), using recombinant gonadotropins (MethodsX, 2019)